Shares of IDEXX Laboratories IDXX were unchanged after the company reported Q1 results.
Quarterly Results
Earnings per share rose 82.17% year over year to $2.35, which beat the estimate of $1.71.
Revenue of $777,707,000 up by 24.17% year over year, which beat the estimate of $737,380,000.
Outlook
The upcoming fiscal year's EPS expected to be between $7.88 and $8.18.
The upcoming fiscal year's revenue expected to be between $3,105,000,000 and $3,160,000,000.
How To Listen To The Conference Call
Date: May 04, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/if4enin4
Recent Stock Performance
Company's 52-week high was at $573.99
Company's 52-week low was at $266.00
Price action over last quarter: Up 13.29%
Company Description
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
